Recombinant Human cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5A), partial

Code CSB-EP524921HU
MSDS
Size Pls inquire
Source E.coli
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP524921HU-B
MSDS
Size Pls inquire
Source E.coli
Conjugate Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-BP524921HU
MSDS
Size Pls inquire
Source Baculovirus
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-MP524921HU
MSDS
Size Pls inquire
Source Mammalian cell
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
>85% (SDS-PAGE)
Target Names
Uniprot No.
Alternative Names
5''-cyclic phosphodiesterase; CGB PDE; CGB-PDE; CGBPDE; cGMP binding cGMP specific 3' 5' cyclic nucleotide phosphodiesterase; cGMP binding cGMP specific 35 cyclic nucleotide phosphodiesterase ; cGMP binding cGMP specific phosphodiesterase; cGMP binding/cGMP specific phosphodiesterase ; cGMP specific 3'5' cyclic phosphodiesterase ; cGMP specific phosphodiesterase PDE5A2; cGMP specific phosphodiesterase type 5A; cGMP-binding cGMP-specific phosphodiesterase; cGMP-specific 3''; CN5A; CN5N; PDE 5; PDE 5A; PDE5; Pde5a; PDE5A_HUMAN; PDE5A1; Phosphodiesterase 5A; Phosphodiesterase 5A cGMP specific; Phosphodiesterase isozyme 5
Species
Homo sapiens (Human)
Protein Length
Partial
Tag Info
Tag type will be determined during the manufacturing process.
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer before Lyophilization
Tris/PBS-based buffer, 6% Trehalose.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP. Specifically regulates nitric-oxide-generated cGMP.
Gene References into Functions
  1. Thsese findings provide insight into the existence of distinct "pools" of PDE5A in human arterial smooth muscle cells and support the idea that these discrete compartments regulate distinct cGMP-dependent events. PMID: 28506928
  2. The analogues showed a relative narrow range of Ki values for PDE5A inhibition (1.2-14 nm). PMID: 28211580
  3. Data indicate that high type 5 phosphodiesterase (PDE5) expression in glioblastoma multiforme (GBM) cells significantly correlated with longer overall survival of patients. PMID: 28099939
  4. the relationship between PDE5A polymorphisms, diabetes, and the efficacy of sildenafil treatment.The response to sildenafil treatment depends on polymorphisms in the PDE5A gene and the glycemic status of the patients. PMID: 27235284
  5. Study showed that past attempts to quantify PDE5 mRNA were flawed due to the use of incorrect primers, and that when correct primers are used, PDE5 mRNA is detectable in human brain tissue; that PDE5 protein exists in human brain by western blot and ELISA; and performed immunohistochemistry and demonstrate that PDE5 is present in human neurons. PMID: 26967220
  6. Our data showed a significant and previously undocumented upregulation of PDE5 in both rat and human BPH. PMID: 26657792
  7. Overexpression of PDE5 in papillary thyroid carcinomas. PMID: 25837309
  8. cGMP PDE isozymes, PDE5 and 10, are elevated in colon tumor cells compared with normal colonocytes, and inhibitors and siRNAs can selectively suppress colon tumor cell growth PMID: 26299804
  9. Results show that Ser102 and Ser104 may influence the conformational flexibility of PDE5A, which may in turn influence phosphorylation status, allosteric regulation by cGMP or other as yet unknown regulatory mechanisms for PDE5A. PMID: 25247292
  10. PDE5A appears to jointly influence amygdala volume and emotion recognition performance. PMID: 25322361
  11. inhibition of PDE5 can counteract apoptosis during aging by modulating proand antiapoptotic molecules and the APP pathway. PMID: 24112792
  12. Myocardial PDE5 expression is increased in the hearts of humans and mice with chronic pressure overload. PMID: 23527037
  13. it is concluded that assessment of PDE5 and PDE9 expression may be useful in the differential diagnosis of benign and malignant breast disease and successful treatment of breast cancer PMID: 22960860
  14. analysis of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6 PMID: 23033484
  15. PDE5 is highly expressed and increases ( approximately 130%) during growth whereas ABCC5 exhibited low to moderate expression, with a moderate increase ( approximately 40%) during growth PMID: 22843873
  16. PDE9 is widely distributed in the urothelial epithelium of the human lower urinary tract and its potential roles may be different from those of PDE5. PMID: 21736695
  17. Treatment of L-1236 with PDE5A-inhibitor sildenafil or with siRNA directed against PDE5A and concomitant stimulation with cyclic guanosine monophosphate (cGMP) resulted in enhanced apoptosis, indicating PDE5A as an oncogene. PMID: 21987443
  18. found in smooth muscle wall of blood vessels transversing the clitoral supepithelial and stromal space PMID: 21697861
  19. the spatial localization of PDE5A at the level of caveolin-rich lipid rafts allows for a feedback loop between endothelial PDE5A and nitric oxide synthase (NOS3) PMID: 21421555
  20. These studies suggest a novel role for PDE5 in erythrocytes. PMID: 21525805
  21. Solved is the crystal structure of the structurally uncharacterized PDE5A GAF-B domain. PMID: 21425347
  22. The distribution of PDE-5 and NOD II may indicate a physiologic role in the regulatory function of human vagina. PMID: 20177899
  23. Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions. PMID: 21193396
  24. In melanoma cells, oncogenic (V600E) BRAF signaling downregulates PDE5A through the transcription factor BRN2, leading to increased cGMP and Ca2+ and the induction of invasion through increased cell contractility. PMID: 21215707
  25. Conformation changes, N-terminal involvement, and cGMP signal relay in the phosphodiesterase-5 GAF domain. PMID: 20861010
  26. PDE5-inhibition blocks TRPC6 channel activation and associated Cn/NFAT activation signaling by PKG-dependent channel phosphorylation PMID: 19961855
  27. Suggest that PDE5A is associated with increased disease susceptibility, pathological progression, and development of proteinuria in childhood IgA nephropathy. PMID: 20563733
  28. The rAd5-shRNA-PDE5A3 can obviously increase the cGMP level in the smooth muscle cells of human corpus cavernosum, and enhance the inhibition of the PDE5 gene. PMID: 19852267
  29. Data show that the identified compound will be a useful agent for evaluating the therapeutic potential of central inhibition of PDE5. PMID: 20196613
  30. High PDE5A1 expression is associated with malignant melanoma. PMID: 20332439
  31. Myocardial oxidative stress increases PDE5 expression in the failing heart PMID: 20308615
  32. Data show that SS increased intracellular cGMP levels and activated protein kinase G, and selectively inhibited PDE5 in breast tumor cells. PMID: 19996273
  33. Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. PMID: 11896473
  34. cGMP-directed regulation of PDE5 phosphorylation and the resulting increase in cGMP binding affinity occur largely within the R domain PMID: 12359732
  35. CGMP-dependent protein kinase I causes NO-induced PDE5 phosphorylation. However, cGMP can directly activate PDE5 without phosphorylation in platelet cytosol, most likely by binding to GAF domains. PMID: 12604588
  36. GAFa domain of PDE5A adopts a structure similar to the GAFb domain of PDE2A, and provides the sole site for cGMP binding in PDE5A PMID: 12650945
  37. three-dimensional structures of the catalytic domain (residues 537-860) of human PDE5 complexed with the three drug molecules sildenafil, tadalafil (Cialis) and vardenafil (Levitra) PMID: 12955149
  38. Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine PMID: 14668322
  39. demonstrated, for the first time, that androgens positively regulate phosphodiesterase 5 PMID: 14764637
  40. no correlations of a novel polymorphism of the PDE5A promoter gene with the intermediate phenotype essential hypertension/erectile dysfunction PMID: 15175637
  41. Phosphorylation of PDE5 seems to act as memory switch for activation leading to long-term desensitization of the signaling pathway. PMID: 15240816
  42. PDE5 gene expression and activity are androgen-dependent in vas deferens. PMID: 15640438
  43. Phosphodiesterase Type 5 is the main factor regulating cyclic guanosine monophosphate hydrolysis and downstream signaling in human PASMCs. PMID: 15817798
  44. Results suggest that glutamine(817) is a positive determinant for phosphodiesterase 5 affinity for cyclic GMP and several inhibitors. PMID: 16407275
  45. Subdomains are structurally and functionally interdependent and act in concert in regulating human PDE5. PMID: 16690614
  46. Virtually all tissues and cell types express PDE5, with heart and cardiomyocytes being contentious; PDE5A1 and PDE5A2 are ubiquitous, but PDE5A3 is specific to smooth muscle, as described in this review. PMID: 17017938
  47. PDE5 may be a possible therapeutic target in bladder dysfunction for ameliorating irritative lower urinary tract symptoms. PMID: 17138653
  48. The PDE-5A was expressed in both pre-adipocytes and adipocytes. PDE-5A mRNA and protein levels decreased as pre-adipocytes differentiated. PMID: 17906676
  49. GAF domains of PDE5A can act as sensors and intracellular sinks for cyclic GMP, but not cyclic AMP. PMID: 18293931
  50. analysis of functional chimeras of the phosphodiesterase 5 and 10 tandem GAF domains PMID: 18635550

Show More

Hide All

Protein Families
Cyclic nucleotide phosphodiesterase family
Tissue Specificity
Expressed in aortic smooth muscle cells, heart, placenta, skeletal muscle and pancreas and, to a much lesser extent, in brain, liver and lung.
Database Links

HGNC: 8784

OMIM: 603310

KEGG: hsa:8654

STRING: 9606.ENSP00000347046

UniGene: Hs.647971

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1